HC Wainwright Maintains Buy on Foghorn Therapeutics With $5 Price Target

HC Wainwright & Co. maintained its Buy rating on Foghorn Therapeutics's stock, setting a price target of $5.00. This target represents a potential upside of 71.2% from the stock's previous close of $2.92.